Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę ""Gene Editing"" wg kryterium: Temat


Tytuł :
DGAT2 stability is increased in response to DGAT1 inhibition in gene edited HepG2 cells.
Autorzy :
McFie PJ; Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5E5, Canada.
Chumala P; Department of Medicine and the Canadian Centre for Health and Safety in Agriculture, University of Saskatchewan, Saskatoon, Saskatchewan S7N 2Z4, Canada.
Katselis GS; Department of Medicine and the Canadian Centre for Health and Safety in Agriculture, University of Saskatchewan, Saskatoon, Saskatchewan S7N 2Z4, Canada.
Stone SJ; Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5E5, Canada. Electronic address: .
Pokaż więcej
Źródło :
Biochimica et biophysica acta. Molecular and cell biology of lipids [Biochim Biophys Acta Mol Cell Biol Lipids] 2021 Sep; Vol. 1866 (9), pp. 158991. Date of Electronic Publication: 2021 Jun 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Editing*
Diacylglycerol O-Acyltransferase/*genetics
Enzyme Stability ; Hep G2 Cells ; Humans
Czasopismo naukowe
Tytuł :
Simultaneous knockout of multiple LHCF genes using single sgRNAs and engineering of a high-fidelity Cas9 for precise genome editing in marine algae.
Autorzy :
Sharma AK; Cell, Molecular Biology and Genomics Group, Department of Biology, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.
Nymark M; Cell, Molecular Biology and Genomics Group, Department of Biology, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.
Flo S; Cell, Molecular Biology and Genomics Group, Department of Biology, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.
Sparstad T; Cell, Molecular Biology and Genomics Group, Department of Biology, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.
Bones AM; Cell, Molecular Biology and Genomics Group, Department of Biology, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.
Winge P; Cell, Molecular Biology and Genomics Group, Department of Biology, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.
Pokaż więcej
Źródło :
Plant biotechnology journal [Plant Biotechnol J] 2021 Aug; Vol. 19 (8), pp. 1658-1669. Date of Electronic Publication: 2021 Apr 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CRISPR-Cas Systems*/genetics
Gene Editing*
Diatoms/*genetics
Base Sequence ; Endonucleases ; RNA, Guide/genetics
Czasopismo naukowe
Tytuł :
Targeting the Highly Expressed microRNA miR-146b with CRISPR/Cas9n Gene Editing System in Thyroid Cancer.
Autorzy :
Santa-Inez DC; Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil.
Fuziwara CS; Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil.
Saito KC; Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil.
Kimura ET; Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Jul 27; Vol. 22 (15). Date of Electronic Publication: 2021 Jul 27.
Typ publikacji :
Journal Article
MeSH Terms :
CRISPR-Cas Systems*
Gene Editing*
Gene Targeting*
MicroRNAs*/biosynthesis
MicroRNAs*/genetics
RNA, Neoplasm*/biosynthesis
RNA, Neoplasm*/genetics
Thyroid Carcinoma, Anaplastic*/genetics
Thyroid Carcinoma, Anaplastic*/metabolism
Thyroid Carcinoma, Anaplastic*/pathology
Thyroid Neoplasms*/genetics
Thyroid Neoplasms*/metabolism
Thyroid Neoplasms*/pathology
Animals ; Cell Line ; Cell Movement/genetics ; Cell Survival/genetics ; Heterografts ; Humans ; Mice ; Neoplasm Transplantation
Czasopismo naukowe
Tytuł :
Harnessing lipid nanoparticles for efficient CRISPR delivery.
Autorzy :
Yan J; Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA. .
Kang DD; Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA. .
Dong Y; Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA. .; Department of Biomedical Engineering; The Center for Clinical and Translational Science; The Comprehensive Cancer Center; Dorothy M. Davis Heart & Lung Research Institute; Department of Radiation Oncology, The Ohio State University, Columbus, Ohio 43210, USA.
Pokaż więcej
Źródło :
Biomaterials science [Biomater Sci] 2021 Sep 14; Vol. 9 (18), pp. 6001-6011. Date of Electronic Publication: 2021 Sep 14.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Gene Editing*
Nanoparticles*
CRISPR-Cas Systems/genetics ; DNA ; Humans ; Lipids
Czasopismo naukowe
Tytuł :
Mitochondrial disease: Replace or edit?
Autorzy :
Adashi EY; Department of Medical Science, Brown University, Providence, RI, USA.
Rubenstein DS; Prisma Health-Upstate, Greenville, SC, USA.
Mossman JA; Aspen Neuroscience, San Diego, CA, USA.
Schon EA; Department of Neurology, and Department of Genetics and Development, Columbia University, New York, NY.
Cohen IG; Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School, Harvard University, Cambridge, MA, USA.
Pokaż więcej
Źródło :
Science (New York, N.Y.) [Science] 2021 Sep 10; Vol. 373 (6560), pp. 1200-1201. Date of Electronic Publication: 2021 Sep 09.
Typ publikacji :
Journal Article
MeSH Terms :
Gene Editing*
Mitochondrial Replacement Therapy*
DNA, Mitochondrial/*genetics
Genetic Therapy/*methods
Mitochondrial Diseases/*genetics
Mitochondrial Diseases/*therapy
Animals ; Humans
Czasopismo naukowe
Tytuł :
Global detection of DNA repair outcomes induced by CRISPR-Cas9.
Autorzy :
Liu M; The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Center for Life Sciences, Genome Editing Research Center, Peking University, Beijing 100871, China.
Zhang W; The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Center for Life Sciences, Genome Editing Research Center, Peking University, Beijing 100871, China.
Xin C; The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Center for Life Sciences, Genome Editing Research Center, Peking University, Beijing 100871, China.
Yin J; The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Center for Life Sciences, Genome Editing Research Center, Peking University, Beijing 100871, China.
Shang Y; State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences; University of Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China.
Ai C; The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Center for Life Sciences, Genome Editing Research Center, Peking University, Beijing 100871, China.
Li J; The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Center for Life Sciences, Genome Editing Research Center, Peking University, Beijing 100871, China.
Meng FL; State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences; University of Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China.
Hu J; The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Center for Life Sciences, Genome Editing Research Center, Peking University, Beijing 100871, China.
Pokaż więcej
Źródło :
Nucleic acids research [Nucleic Acids Res] 2021 Sep 07; Vol. 49 (15), pp. 8732-8742.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CRISPR-Associated Protein 9*
CRISPR-Cas Systems*
DNA Repair*
Gene Editing*
Animals ; Cells, Cultured ; Computer Simulation ; Humans ; Mice ; Plasmids/genetics ; Sequence Deletion ; Translocation, Genetic
Czasopismo naukowe
Tytuł :
Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
Autorzy :
Huang RS; Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.
Lai MC; Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.; Institute of Biochemical Sciences, National Taiwan University, Taipei, Taiwan.
Lin S; Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.; Institute of Biochemical Sciences, National Taiwan University, Taipei, Taiwan.
Pokaż więcej
Źródło :
Current protocols [Curr Protoc] 2021 Sep; Vol. 1 (9), pp. e246.
Typ publikacji :
Journal Article
MeSH Terms :
CRISPR-Cas Systems*/genetics
Gene Editing*
Gene Knockout Techniques ; Humans ; Immunotherapy, Adoptive ; Killer Cells, Natural
Czasopismo naukowe
Tytuł :
Kazuto Kato: the ethics of editing humanity.
Źródło :
Bulletin of the World Health Organization [Bull World Health Organ] 2021 Sep 01; Vol. 99 (9), pp. 616-617.
Typ publikacji :
Historical Article; News
MeSH Terms :
Bioethical Issues*/history
Ethics, Medical*/history
Biotechnology/*ethics
Gene Editing/*ethics
CRISPR-Cas Systems ; Ethical Theory ; Gene Editing/history ; History, 21st Century ; Human Characteristics ; Humans
Personal Name as Subject :
Kato K
Periodyk
Tytuł :
A unified model of human hemoglobin switching through single-cell genome editing.
Autorzy :
Shen Y; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Verboon JM; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Zhang Y; Children's Medical Center Research Institute, Department of Pediatrics, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Liu N; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Kim YJ; Children's Medical Center Research Institute, Department of Pediatrics, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Marglous S; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Harvard Stem Cell Institute, Cambridge, MA, USA.
Nandakumar SK; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Voit RA; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Fiorini C; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Ejaz A; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Basak A; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Orkin SH; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Harvard Stem Cell Institute, Cambridge, MA, USA.; Howard Hughes Medical Institute, Boston, MA, USA.
Xu J; Children's Medical Center Research Institute, Department of Pediatrics, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Sankaran VG; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. .; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. .; Broad Institute of MIT and Harvard, Cambridge, MA, USA. .; Harvard Stem Cell Institute, Cambridge, MA, USA. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Aug 17; Vol. 12 (1), pp. 4991. Date of Electronic Publication: 2021 Aug 17.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Editing*
Hemoglobins/*genetics
Hemoglobins/*metabolism
CRISPR-Cas Systems ; Chromatin ; Chromosomes ; DNA-Binding Proteins/metabolism ; Fetal Hemoglobin/genetics ; Fetal Hemoglobin/metabolism ; Gene Expression ; Globins ; Humans ; Mutation ; Repressor Proteins ; Transcription Factors/metabolism ; beta-Globins/genetics
Czasopismo naukowe
Tytuł :
Anthocyanin Biosynthesis Genes as Model Genes for Genome Editing in Plants.
Autorzy :
Khusnutdinov E; Institute of Biochemistry and Genetics, Ufa Federal Research Center RAS, Prospekt Oktyabrya 71, 450054 Ufa, Russia.
Sukhareva A; Institute of Biochemistry and Genetics, Ufa Federal Research Center RAS, Prospekt Oktyabrya 71, 450054 Ufa, Russia.
Panfilova M; Institute of Biochemistry and Genetics, Ufa Federal Research Center RAS, Prospekt Oktyabrya 71, 450054 Ufa, Russia.
Mikhaylova E; Institute of Biochemistry and Genetics, Ufa Federal Research Center RAS, Prospekt Oktyabrya 71, 450054 Ufa, Russia.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Aug 15; Vol. 22 (16). Date of Electronic Publication: 2021 Aug 15.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anthocyanins*/biosynthesis
Anthocyanins*/genetics
Gene Editing*
Genes, Plant*
Models, Genetic*
Plants*/genetics
Plants*/metabolism
Czasopismo naukowe
Tytuł :
Approaches to Enhance Precise CRISPR/Cas9-Mediated Genome Editing.
Autorzy :
Denes CE; The Dr. John and Anne Chong Lab for Functional Genomics, Charles Perkins Centre and School of Life & Environmental Sciences, The University of Sydney, Sydney, NSW 2006, Australia.
Cole AJ; Centenary Institute, The University of Sydney, Sydney, NSW 2006, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
Aksoy YA; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia.; Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW 2113, Australia.
Li G; The Dr. John and Anne Chong Lab for Functional Genomics, Charles Perkins Centre and School of Life & Environmental Sciences, The University of Sydney, Sydney, NSW 2006, Australia.
Neely GG; The Dr. John and Anne Chong Lab for Functional Genomics, Charles Perkins Centre and School of Life & Environmental Sciences, The University of Sydney, Sydney, NSW 2006, Australia.; Centenary Institute, The University of Sydney, Sydney, NSW 2006, Australia.
Hesselson D; Centenary Institute, The University of Sydney, Sydney, NSW 2006, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Aug 09; Vol. 22 (16). Date of Electronic Publication: 2021 Aug 09.
Typ publikacji :
Journal Article; Review
MeSH Terms :
CRISPR-Cas Systems*
DNA Breaks, Double-Stranded*
DNA End-Joining Repair*
Gene Editing*
Models, Genetic*
Recombinational DNA Repair*
Animals ; Humans
Czasopismo naukowe
Tytuł :
Cellular Models in Schizophrenia Research.
Autorzy :
Abashkin DA; Mental Health Research Center, Clinical Genetics Laboratory, Kashirskoe Sh. 34, 115522 Moscow, Russia.
Kurishev AO; Mental Health Research Center, Clinical Genetics Laboratory, Kashirskoe Sh. 34, 115522 Moscow, Russia.
Karpov DS; Mental Health Research Center, Clinical Genetics Laboratory, Kashirskoe Sh. 34, 115522 Moscow, Russia.; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov Str. 32, 119991 Moscow, Russia.
Golimbet VE; Mental Health Research Center, Clinical Genetics Laboratory, Kashirskoe Sh. 34, 115522 Moscow, Russia.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Aug 07; Vol. 22 (16). Date of Electronic Publication: 2021 Aug 07.
Typ publikacji :
Journal Article; Review
MeSH Terms :
CRISPR-Cas Systems*
Gene Editing*
Gene Expression Regulation*
Models, Neurological*
Schizophrenia*/genetics
Schizophrenia*/metabolism
Biomedical Research ; Genome-Wide Association Study ; Humans
Czasopismo naukowe
Tytuł :
Gene Editing - A Cure for Transthyretin Amyloidosis?
Autorzy :
Maurer MS; From the Clinical Cardiovascular Research Laboratory for the Elderly, Columbia University Irving Medical Center, New York Presbyterian Hospital, New York.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Aug 05; Vol. 385 (6), pp. 558-559.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Amyloid Neuropathies, Familial*/genetics
Amyloid Neuropathies, Familial*/therapy
Gene Editing*
Humans
SCR Disease Name :
Amyloidosis, Hereditary, Transthyretin-Related
Opinia redakcyjna
Tytuł :
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
Autorzy :
Gillmore JD; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Gane E; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Taubel J; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Kao J; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Fontana M; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Maitland ML; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Seitzer J; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
O'Connell D; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Walsh KR; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Wood K; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Phillips J; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Xu Y; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Amaral A; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Boyd AP; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Cehelsky JE; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
McKee MD; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Schiermeier A; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Harari O; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Murphy A; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Kyratsous CA; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Zambrowicz B; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Soltys R; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Gutstein DE; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Leonard J; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Sepp-Lorenzino L; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Lebwohl D; From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George's University of London (J.T.) - both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) - all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Aug 05; Vol. 385 (6), pp. 493-502. Date of Electronic Publication: 2021 Jun 26.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
CRISPR-Cas Systems*
Gene Editing*
Amyloid Neuropathies, Familial/*genetics
Amyloid Neuropathies, Familial/*therapy
Prealbumin/*genetics
Female ; Gene Transfer Techniques ; Humans ; Infusions, Intravenous ; Liposomes ; Male ; Middle Aged ; Nanoparticles ; Prealbumin/analysis ; RNA, Messenger
SCR Disease Name :
Amyloidosis, Hereditary, Transthyretin-Related
Czasopismo naukowe
Tytuł :
BARBEKO'ing in the lab: Versatile CRISPR screens with barcoded base editors.
Autorzy :
Chatterjee P; Wyss Institute for Biologically Inspired Engineering, Harvard University, Cambridge, MA, USA; Department of Genetics, Harvard Medical School, Cambridge, MA, USA; Center for Bits and Atoms, Cambridge, MA, USA; MIT Media Lab, Massachusetts Institute of Technology, Cambridge, MA, USA. Electronic address: .
Pokaż więcej
Źródło :
Molecular cell [Mol Cell] 2021 Aug 05; Vol. 81 (15), pp. 3046-3047.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Comment
MeSH Terms :
Clustered Regularly Interspaced Short Palindromic Repeats*
Gene Editing*
CRISPR-Cas Systems ; Cytosine ; Reproducibility of Results
Czasopismo naukowe
Tytuł :
Delivery of exogenous proteins into eggs by injection into the mother's ovary (IMO) in zebrafish.
Autorzy :
Iwaizumi M; Laboratory of Marine Life Science and Genetics, Graduate School of Agricultural Science, Tohoku University, Sendai, 980-0845, Japan.
Yokoi H; Laboratory of Marine Life Science and Genetics, Graduate School of Agricultural Science, Tohoku University, Sendai, 980-0845, Japan. .
Suzuki T; Laboratory of Marine Life Science and Genetics, Graduate School of Agricultural Science, Tohoku University, Sendai, 980-0845, Japan. .
Pokaż więcej
Źródło :
Fish physiology and biochemistry [Fish Physiol Biochem] 2021 Aug; Vol. 47 (4), pp. 849-855. Date of Electronic Publication: 2021 Mar 20.
Typ publikacji :
Journal Article
MeSH Terms :
Gene Editing/*methods
Zebrafish/*genetics
Zygote/*metabolism
Animals ; CRISPR-Associated Protein 9/genetics ; Female ; Fish Proteins/genetics ; Fluorescence ; Gene Editing/veterinary ; Green Fluorescent Proteins/genetics ; Green Fluorescent Proteins/metabolism ; Injections ; Luciferases/genetics ; Luciferases/metabolism ; Ovary ; RNA/genetics ; Recombinant Proteins ; Zebrafish/metabolism
Czasopismo naukowe
Tytuł :
Editorial commentary: A careful approach to gene editing.
Autorzy :
Donahue JK; From the Division of Cardiology, University of Massachusetts Medical School, 55 Lake Avenue-North, Worcester, MA 01655, United States. Electronic address: .
Pokaż więcej
Źródło :
Trends in cardiovascular medicine [Trends Cardiovasc Med] 2021 Aug; Vol. 31 (6), pp. 349-350. Date of Electronic Publication: 2020 Aug 26.
Typ publikacji :
Editorial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Comment
MeSH Terms :
Gene Editing*
Humans
Raport
Tytuł :
Base editing-mediated perturbation of endogenous PKM1/2 splicing facilitates isoform-specific functional analysis in vitro and in vivo.
Autorzy :
Lin J; Precise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, China.
Wu S; Precise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, China.
Shen Q; Centre for Cell Lineage and Atlas (CCLA), Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China.
Liu J; Precise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, China.
Huang S; School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Peng G; Centre for Cell Lineage and Atlas (CCLA), Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China.
Qiao Y; Precise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, China.
Pokaż więcej
Źródło :
Cell proliferation [Cell Prolif] 2021 Aug; Vol. 54 (8), pp. e13096. Date of Electronic Publication: 2021 Jul 09.
Typ publikacji :
Journal Article
MeSH Terms :
Gene Editing*
Pyruvate Kinase/*metabolism
Alternative Splicing ; Animals ; Cell Cycle Proteins/genetics ; Cell Cycle Proteins/metabolism ; Cell Proliferation ; Clustered Regularly Interspaced Short Palindromic Repeats/genetics ; Down-Regulation ; Exons ; Female ; HCT116 Cells ; Humans ; Mutagenesis ; Protein Isoforms/genetics ; Protein Isoforms/metabolism ; Pyruvate Kinase/genetics ; Up-Regulation ; Zebrafish/metabolism ; Zebrafish Proteins/genetics ; Zebrafish Proteins/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies